Investment analysts at CIBC began coverage on shares of Outlook Therapeutics (NASDAQ:OTLK) in a report issued on Thursday, FirstToMarketsRatingsTable reports. The firm set an “outperform” rating and a $12.00 price target on the stock.
Several other equities research analysts have also issued reports on OTLK. ValuEngine lowered shares of Outlook Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th. Ascendiant Capital Markets initiated coverage on shares of Outlook Therapeutics in a research note on Monday, April 22nd. They set a “buy” rating and a $4.00 target price on the stock. Finally, Oppenheimer initiated coverage on shares of Outlook Therapeutics in a research note on Thursday. They set an “outperform” rating and a $12.00 target price on the stock.
NASDAQ:OTLK traded up $0.34 during mid-day trading on Thursday, hitting $1.37. The company’s stock had a trading volume of 16,389,007 shares, compared to its average volume of 347,497. Outlook Therapeutics has a 1 year low of $0.85 and a 1 year high of $10.96.
Outlook Therapeutics (NASDAQ:OTLK) last posted its earnings results on Wednesday, May 15th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.08. The firm had revenue of $0.64 million for the quarter.
A hedge fund recently bought a new stake in Outlook Therapeutics stock. Renaissance Technologies LLC bought a new position in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 11,166 shares of the company’s stock, valued at approximately $83,000. Renaissance Technologies LLC owned approximately 0.10% of Outlook Therapeutics as of its most recent SEC filing. Institutional investors own 4.60% of the company’s stock.
About Outlook Therapeutics
Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.
Further Reading: What is a Derivative?
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.